Series C · Biotech
Delix Therapeutics closes $100 million Series C for neuroscience pipeline
JJDC and SV Health Investors’ Dementia Discovery Fund led the financing.
Delix Therapeutics announced a $100 million Series C on November 9, 2026, led by Johnson & Johnson Innovation – JJDC, Inc. and SV Health Investors’ Dementia Discovery Fund.
The funding will advance zalsupindole through Phase II development in major depressive disorder and support the company’s broader neuroplastogen pipeline. Delix expects to begin the Phase II trial in the first half of 2027.
Use of funds
Advance zalsupindole through Phase II development
Develop broader neuroplastogen pipeline